Form 4: IO Biotech CEO Mai-Britt Zocca Acquires 750,000 Stock Options
SEC Form 4 Filing
IO Biotech's CEO, Mai-Britt Zocca, acquired 750,000 stock options on March 15, 2024, according to a Form 4 filing.
Summary
- Mai-Britt Zocca, CEO of IO Biotech, acquired 750,000 stock options on March 15, 2024.
- The exercise price of these options is $1.65.
- The options vest over time, with one-fourth vesting on March 15, 2025, and the remainder vesting monthly thereafter, contingent on continued service.
- The options have accelerated vesting under certain termination scenarios.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it is a standard disclosure of stock option grants. The vesting schedule is a positive sign of long-term commitment.
Positives
- The acquisition of stock options by the CEO aligns her interests with those of the shareholders.
- The vesting schedule incentivizes continued service and commitment to the company's long-term success.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the compensation and equity ownership of key executives.
Stakeholder Impact
- The stock option grant aligns the CEO's interests with those of shareholders, potentially incentivizing value creation.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Date of transaction: CEO acquired 750,000 stock options. |
| 03/15/2025 | Date when one-fourth of the options vest. |
| 03/15/2034 | Expiration date of the stock options. |
| 03/18/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.